Skip to main content

Stratagene Shares Rise on Agilent Acquisition Pact

Shares in Stratagene rose 28.8 percent for the four-day trading week ended Tuesday after Agilent signed a deal to buy the firm for $10.94 a share (see related article this issue). The acquisition price represents a 28 percent premium over Stratagene’s closing price the day before the deal was announced.
 
Stratagene led all gainers for the week. Shares in Third Wave Technologies registered the second-biggest increase for the tracking period, rising 10.6 percent.
 
Beckman Coulter led the four firms that declined for the week. Shares in the firm dropped 3 percent after Inverness Medical Innovations made a rival acquisition bid for Biosite.
 
Overall, the BCW Index gained 1.2 percent for the trading week, which was a day shorter due to the Good Friday holiday. The Dow Jones Industrial Average was up .5 percent, the Nasdaq rose 1.1 percent, and the Nasdaq Biotech Index gained 2.6 percent for the week.

 
 
 

 
BioCommerce Week Index of Diversified
Molecular Biology Tool Companies
Company
Ticker
Closing Price (April 10, 2007)
Starting Price
(
April 4, 2007)
% change
Affymetrix
AFFX
31.17
30.42
2.47
Agilent
A
34.91
34.55
1.04
Applied Biosystems
ABI
30.55
29.34
4.12
Beckman
BEC
63.81
65.76
-2.97
Becton Dickinson
BDX
77.93
78.89
-1.22
Bio-Rad
BIO
70.36
69.99
0.53
Bruker
BRKR
10.65
10.57
0.76
Caliper
CALP
5.84
5.69
2.64
Cepheid
CPHD
11.62
11.47
1.31
Illumina
ILMN
31.56
29.5
6.98
Invitrogen
IVGN
65.39
63.99
2.19
Luminex
LMNX
13.92
13.9
0.14
MDS
MDZ
19.08
18.77
1.65
Millipore
MIL
73.11
72.61
0.69
PerkinElmer
PKI
24.6
24.44
0.65
Qiagen
QGEN
17.49
17.66
-0.96
Sequenom
SQNM
3.71
3.8
-2.37
Sigma-Aldrich
SIAL
42.19
42.11
0.19
Stratagene
STGN
10.7
8.31
28.76
Thermo
TMO
48.24
46.72
3.25
Third Wave
TWTI
5.86
5.3
10.57
Waters
WAT
59.75
59.52
0.39
BCW Index Average  
34.20
33.79
1.23
The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.